PDGFβ receptor blockade inhibits intimal hyperplasia in the baboon

Circulation

Volumn 99, Issue 4, 1999, Pages 564-569

  Hart, Charles E ^a   Kraiss, Larry W ^b   Vergel, Selina ^c   Gilbertson, Debra ^a   Kenagy, Richard ^c   Kirkman, Thomas ^d   Crandall, David L ^e   Tickle, Simon ^f   Finney, Helene ^f   Yarranton, Geoff ^f   Clowes, Alexander W ^c  

^a ZYMOGENETICS INC   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d BioDevelopment Associates   (United States)

^e PFIZER INC   (United States)

^f UCB PHARMA   (Belgium)

Author keywords

Angioplasty; Antibodies; Balloon; Platelet derived factors; Receptors; Restenosis

Indexed keywords

BROXURIDINE; CHIMERIC ANTIBODY; HEPARIN; PLATELET DERIVED GROWTH FACTOR B; PLATELET DERIVED GROWTH FACTOR RECEPTOR; RECEPTOR ANTIBODY; MONOCLONAL ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY INTIMA PROLIFERATION; ARTERY MEDIA; ARTICLE; BABOON; BLOOD VESSEL INJURY; CONTROLLED STUDY; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; RECEPTOR BLOCKING; SAPHENOUS VEIN; SUBCUTANEOUS DRUG ADMINISTRATION; VASCULAR SMOOTH MUSCLE; ANIMAL; BALLOON DILATATION; CELL DIVISION; DRUG ANTAGONISM; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; HYPERPLASIA; IMMUNOLOGY; INTIMA; METABOLISM; PAPIO; PARTIAL THROMBOPLASTIN TIME; PATHOLOGY; TIME;

ANIMALS; ANTIBODIES, MONOCLONAL; BALLOON DILATATION; CELL DIVISION; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEPARIN; HYPERPLASIA; PAPIO; PARTIAL THROMBOPLASTIN TIME; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; TIME FACTORS; TUNICA INTIMA;

EID: 0033514094     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.99.4.564     Document Type: Article

References (24)

1. Sirois MG, Simons M, Edelman ER. Antisense oligonucleotide inhibition of PDGF-β receptor subunit expression directs suppression of intimal thickening. Circulation. 1997;95:669-676.
2. Fingerle J, Johnson R, Clowes AW, Majesky MW, Reidy MA. Role of platelets in smooth muscle cell proliferation and migration after vascular injury in rat carotid artery. Proc Natl Acad Sci U S A. 1989;86: 8412-8416.
3. Ferns GAA, Raines EW, Sprugel KH, Motani AS, Reidy MA, Ross R. Inhibition of neointimal smooth muscle accumulation after angioplasty by an antibody to PDGF. Science. 1991;253:1129-1132.
4. Jawien A, Bowen-Pope DF, Lindner V, Schwartz SM, Clowes AW. Platelet-derived growth factor promotes smooth muscle migration and intimal thickening in a rat model of balloon angioplasty. J Clin Invest. 1992;89:507-511.
5. Kraiss LW, Raines EW, Wilcox JN, Seifert RA, Barrett TB, Kirkman TR, Hart CE, Bowen-Pope DF, Ross R, Clowes AW. Regional expression of the platelet-derived growth factor and its receptors in a primate graft model of vessel wall assembly. J Clin Invest. 1993;92:338-348.
6. Barrett TB, Benditt EP. Platelet-derived growth factor gene expression in human atherosclerotic plaques and normal artery wall. Proc Natl Acad Sci U S A. 1988;85:2810-2814.
7. Wilcox JN, Smith KM, Williams LT, Schwartz SM, Gordon D. Platelet-derived growth factor mRNA detection in human atherosclerotic plaques by in situ hybridization. J Clin Invest. 1988;82:1134-1143.
8. Ross R, Masuda J, Raines EW, Gown AM, Katsuda S, Sasahara M, Malden LT, Masuko H, Sato H. Localization of PDGF-B protein in macrophages in all phases of atherogenesis. Science. 1990;248: 1009-1012.
9. Koyama N, Hart CE, Clowes AW. Different functions of the platelet-derived growth factor-α and -β receptors for the migration and proliferation of cultured baboon smooth muscle cells. Circ Res. 1994;75: 682-691.
10. Clowes AW, Clowes MM. Kinetics of cellular proliferation after arterial injury, IV: heparin inhibits rat smooth muscle mitogenesis and migration. Circ Res. 1986;58:839-845.
11. Geary RL, Koyama N, Wang TW, Vergel S, Clowes AW. Failure of heparin to inhibit intimal hyperplasia in injured baboon arteries: the role of heparin-sensitive and -insensitive pathways in the stimulation of smooth muscle cell migration and proliferation. Circulation. 1995;91: 2972-2981.
12. Tiesman J, Hart CE. Identification of a soluble receptor for platelet-derived growth factor in cell-conditioned medium and human plasma. J Biol Chem. 1993;268:9621-9628.
13. King DK, Adair JR, Angal S, Low DC, Proudfoot KA, Lloyd JC, Bodmer M, Yarranton GT. Expression, purification and characterization of a mouse:human chimeric antibody and chimeric Fab' fragment. Biochem J. 1992;281:317-323.
14. Bebbington CR, Renner G, Thomson S, King DK, Abrams D, Yarranton GT. High level expression of a recombinant antibody from myeloma cells using a glutamine synthetase gene as an amplifiable, selectable marker. Biotechnology. 1992;10:169-175.
15. Herrman J-PR, Hermans WRM, Vos J, Serruys PW. Pharmacological approaches to the prevention of restenosis following angioplasty, I: the search for the holy grail? Drugs. 1993;46:18-52.
16. Herrman J-PR, Hermans WRM, Vos J, Serruys PW. Pharmacological approaches to the prevention of restenosis following angioplasty, II: the search for the holy grail? Drugs. 1993;46:249-262.
17. Pratt RE, Dzau VJ. Pharmacological strategies to prevent restenosis: lessons learned from blockade of the renin-angiotensin system. Circulation. 1996;93:848-852.
18. Shaw LA, Rudin M, Cook NS. Pharmacological inhibition of restenosis: learning from experience. Trends Pharmacol Sci. 1995;16:401-404.
19. Clowes AW, Karnovsky MJ. Suppression by heparin of smooth muscle cell proliferation in injured arteries. Nature. 1977;265:625-626.
20. Banai S, Wolf Y, Golomb G, Pearle A, Waltenberger J, Fishbein I, Schneider A, Gazit A, Perez L, Huber R, Lazarovichi G, Rabinovich L, Levitzki A, Gertz SD. PDGF-receptor tyrosine kinase blocker AG1295 selectively attenuates smooth muscle cell growth in vitro and reduces neointimal formation after balloon angioplasty in swine. Circulation. 1998;97:1960-1969.
21. EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med. 1994;330:956-961.
22. Karsch KR, Preisack MB, Baildon R, Eschenfelder V, Foley D, Garcia EJ, Kaltenbach M, Meisner C, Selbmann HK, Serruys PW, Shiu MF, Sujatta M, Bonan R. Low molecular weight heparin (reviparin) in percutaneous transluminal coronary angioplasty: results of a randomized, double-blind, unfractionated heparin and placebo-controlled, multicenter trial (REDUCE trial). J Am Coll Cardiol. 1996;28:1437-1443.
23. Lablanche JM, McFadden EP, Meneveau N, Lusson JR, Bertrand B, Metzger JP, Legrand V, Grollier G, Macaya C, De Bruyne B, Vahanian A, Grentzinger A, Masquet C, Wolf JE, Tobelem G, Fontecave S, Vacheron A, D'Azemar P, Bertrand ME. Effect of nadroparin, a low-molecular-weight heparin, on clinical and angiographic restenosis after coronary balloon angioplasty: the FACT study. Circulation. 1997;96: 3396-3402.
24. Geary RL, Kohler TR, Vergel S, Kirkman TR, Clowes AW. Time course of flow-induced smooth muscle cell proliferation and intimal thickening in endothelialized baboon vascular grafts. Circ Res. 1994;74:14-23.